Back to discover
Disease

Drug Hypersensitivity

Late-stage therapeutic developmentEmerging research
MeSHDrug Hypersensitivity
2
Publications
6
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Immune checkpoint blockade lowers the threshold of naïve T-cell priming to drug-associated antigens in a dose-dependent fashion.

Research2024-11-01Toxicological sciences : an official journal of the Society of Toxicology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2028.
Upcoming Milestones
Major developments
Upcoming trial readoutImportant
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Results expected Q3 20282026-05-26
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
6
All trials
1
Active
1
Late-stage
4
Completed
Late-stage studies

Treatment of DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) With Tegeline®

Phase 3 · Terminated · University Hospital, Rouen
Recruiting

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Phase 2 · Recruiting · Massachusetts General Hospital

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20202024
Major themes5
  • Drug Hypersensitivity2
  • Dose-Response Relationship, Drug1
  • Hypersensitivity, Immediate1
  • Immune Checkpoint Inhibitors1
  • T-Lymphocytes1
Leading journals2
  • Allergy1
  • Toxicological sciences : an official journal of the Society of Toxicology1
Leading researchers8
  • Atanaskovic-Markovic M1
  • Barbaud A1
  • Betts C1
  • Bircher AJ1
  • Brockow K1
  • Caubet JC1
  • Celik G1
  • Cernadas J1
Affiliations (unnormalised)6
  • Allergy Clinic1
  • Ankara University School of Medicine1
  • Centre for Drug Safety Science1
  • Centro Hospitalar Universitário de S João1
  • Clinical Immunology and Allergy Unit1
  • Clinical Pharmacology and Safety Science1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Immunologically mediated adverse reactions to medicinal substances used legally or illegally.

Identifiers
MeSHDrug Hypersensitivity
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.